Prot# INCB 8721 RVT-901: A Long-Term Open-Label Non-Randomized Study to Evaluate the Safety of 100 and 200mg Reverset? (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects When Used in Combination with Other Antiretroviral Agents

Project: Research project

Project Details

Effective start/end date4/7/058/6/08


  • Quintiles, Inc. (INCB 8721 RVT-901 // INCB 8721 RVT-901)
  • Incyte Corporation (INCB 8721 RVT-901 // INCB 8721 RVT-901)